Limited Market Release (LMR) of the LIBERTY® System is on ScheduleBuilding on Positive Customer Feedback and Growing Market Enthusiasm, the ...

We can readily understand why investors are attracted to unprofitable companies. By way of example, Microbot Medical (NASDAQ:MBOT) has seen its share price rise 142% over the last year, delighting ...

Fintel reports that on December 3, 2025, Roth Capital initiated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. Analyst Price Forecast Suggests 453.85% Upside As of November 17 ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

HINGHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, announced that Emory University ...

Investing.com - H.C. Wainwright has reiterated its Buy rating on Microbot Medical (NASDAQ:MBOT) with a price target of $12.00 following the company’s third-quarter 2025 financial results. This target ...

Fintel reports that on October 15, 2025, HC Wainwright & Co. reiterated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. Analyst Price Forecast Suggests 325.00% Upside As of ...

We recently published 10 Stocks Losing Big Amid Market Boom. Microbot Medical Inc. (NASDAQ:MBOT) is one of the worst performers on Thursday. Microbot extended its losing streak to a fourth consecutive ...

HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT), developer of the innovative LIBERTY ® Endovascular Robotic System, announced it has been approved to receive a ...

The Army will review the use of selection boards to assess senior soldiers for command positions, officials said. In a memo Thursday, Secretary of the Army Dan Driscoll rescinded the official status ...

Microbot Medical Inc. (MBOT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.